147 related articles for article (PubMed ID: 30742560)
21. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series.
Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Postigo C; Cortijo-Cascajares S; Ortiz-Romero PL
Int J Dermatol; 2024 Feb; 63(2):e57-e59. PubMed ID: 38093412
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
Hui L; von Keudell G; Wang R; Zeidan AM; Gore SD; Ma X; Davidoff AJ; Huntington SF
Cancer; 2017 Oct; 123(19):3763-3771. PubMed ID: 28640385
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.
Flerlage JE; Metzger ML; Wu J; Panetta JC
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1217-1223. PubMed ID: 27837256
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab vedotin related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity?
Diebert N; Baker K; Fernández KS
Pediatr Blood Cancer; 2022 Jun; 69(6):e29444. PubMed ID: 34767681
[No Abstract] [Full Text] [Related]
25. Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Sep; 19(9):1144-1146. PubMed ID: 30122617
[No Abstract] [Full Text] [Related]
26. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.
Wang CC; Thanh C; Gibson EA; Ball-Burack M; Hogan LE; Descours B; Jones N; Carvidi AB; Munter S; Bakkour S; Busch MP; Milush JM; Deeks SG; Henrich TJ
Blood Adv; 2018 Dec; 2(23):3479-3482. PubMed ID: 30530753
[TBL] [Abstract][Full Text] [Related]
27. A rare case of early-onset lymphomatoid papulosis refractory to brentuximab vedotin.
Ferranti M; Salmaso R; Marino D; Alaibac M
Dermatol Ther; 2021 May; 34(3):e14943. PubMed ID: 33719147
[No Abstract] [Full Text] [Related]
28. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
32. Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
Oymanns M; Daum-Marzian M; Bellm A; Elsayad K; Eich HT; Assaf C
Br J Dermatol; 2023 Jan; 188(1):145-146. PubMed ID: 36689504
[No Abstract] [Full Text] [Related]
33. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
34. Getting to transplant in Hodgkin lymphoma: BVB.
Gordon LI
Blood; 2018 Jul; 132(1):1-3. PubMed ID: 29976776
[No Abstract] [Full Text] [Related]
35. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
Faulk KE; Sopfe JM; Campbell K; Liptzin DR; Liu AK; Franklin ARK; Cost CR
Br J Haematol; 2018 Oct; 183(2):251-256. PubMed ID: 30198571
[TBL] [Abstract][Full Text] [Related]
36. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
37. Refractory Hodgkin lymphoma: time for targeted therapies?
Brice P
Blood; 2018 Mar; 131(11):1156-1157. PubMed ID: 29545402
[No Abstract] [Full Text] [Related]
38. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
39. Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?
Crump M
J Clin Oncol; 2021 Jan; 39(2):97-99. PubMed ID: 33275485
[No Abstract] [Full Text] [Related]
40. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]